modernretina.com

Webseiten-Bericht für modernretina.com

Modern Retina – Ophthalmology News, Events & Expert Insights

 Generiert am 31 März 2026 15:12 PM

Aktuelle Statistiken? UPDATE !

Der Wert ist 57/100

SEO Inhalte

Seitentitel

Modern Retina – Ophthalmology News, Events & Expert Insights

Länge : 60

Perfekt, denn Ihr Seitentitel enthält zwischen 10 und 70 Anzahl Zeichen.

Seitenbeschreibung

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Länge : 155

Großartig, denn Ihre Seitenbeschreibung enthält zwischen 70 und 160 Anzahl Zeichen.

Suchbegriffe

Nicht so gut. Wir konnten keine META-Suchbegriffe auf Ihrer Webseite finden. Benutzen Sie dieses kostenlose Werkzeug um META-Suchbegriffe zu erzeugen.

Og META Eigenschaften

Sehr gut, denn diese Webseite nutzt die Vorteile aus den Og Properties.

Eigenschaft Inhalt
title Modern Retina
type website
image https://www.modernretina.com/MR_Hover_Logo.jpg
url https://www.modernretina.com/
image:url https://www.modernretina.com/MR_Hover_Logo.jpg
image:width 1200
image:height 630
image:alt Modern Retina – Ophthalmology News, Events & Expert Insights

Überschriften

H1 H2 H3 H4 H5 H6
1 56 46 4 16 0
  • [H1] Latest News
  • [H2] Conference Coverage
  • [H2] Trending on Modern Retina
  • [H2] Shorts
  • [H2] Podcasts
  • [H2] Videos
  • [H2] Modern Retina Digital Edition
  • [H2] Continuing Medical Education
  • [H2] (CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] (COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] (CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] Practical Approaches to Modern Dry Eye Treatment and Management
  • [H2] (COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] 20th Annual Controversies in Modern Eye Care
  • [H2] (CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] (COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Collaborative Care Symposium
  • [H2] Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
  • [H2] (CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] (COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop
  • [H2] (COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] (CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] Interventional Dry Eye: A Stepwise Treatment & Management Approach
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] (CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management
  • [H2] (CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment
  • [H2] (CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice
  • [H2] (CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP
  • [H2] All News
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS
  • [H3] The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD
  • [H3] Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME
  • [H3] The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD
  • [H3] PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice
  • [H3] PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice
  • [H3] Integrating AI to manage DR in a primary care setting
  • [H3] What to expect from virtual AAO 2020
  • [H3] Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion
  • [H3] Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
  • [H3] Ophthalmic drug shortages more frequent, longer lasting than average
  • [H3] Johnson & Johnson’s TECNIS PureSee EDOF IOL cleared for US market
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] NovaBridge, Visara report positive phase 2a results for dual VEGF-A/ANG-2 inhibitor VIS-101
  • [H3] FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
  • [H3] Ocugen completes enrollment in liMeliGhT phase 3 trial of OCU400 for retinitis pigmentosa
  • [H3] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H3] Q&A: AI-predicted retinal function shows promise in geographic atrophy
  • [H3] Dr. Mali’s top 5 predictions in ophthalmology for 2026
  • [H3] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H3] Q&A: Gennady Landa, MD, shares clinical insights on the ranibizumab ocular implant
  • [H3] Samsung Bioepis reaches settlement agreement for Eylea (aflibercept) biosimilar
  • [H3] ISS 2026 highlights advances in ophthalmic imaging for retinal practice
  • [H3] American College of Physicians policy paper urges medical community to drop the term “'provider"
  • [H3] PRIMA System: A major step in the battle against GA
  • [H3] MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
  • [H3] Metformin use associated with reduced incidence of intermediate AMD
  • [H3] FDA decision: Carbachol–brimonidine ophthalmic solution approved for presbyopia following BRIO phase 3 results
  • [H3] New optoretinography technique allows direct measurement of rod function in vivo
  • [H3] Navigating geographic atrophy from biomarkers to bilateral therapy
  • [H3] Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Long-lived Greenland sharks may point to new approaches for retinal disease
  • [H3] Molecular insights and clinical experience: Extending anti-VEGF durability
  • [H3] Q&A: Evolving approaches to geographic atrophy management
  • [H3] Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
  • [H3] Rates of retinal layer thinning predict visual field progression in glaucoma
  • [H3] First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
  • [H3] FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
  • [H3] 8 things to know about aflibercept 8 mg for retinal vascular disease
  • [H3] A new treatment round-up for AMD and GA
  • [H4] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H4] Phase 2 topline data: Ocugen OCU410 reduces geographic atrophy lesion growth by 31% at 12 months
  • [H4] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H4] ONL Therapeutics randomizes first European patient in phase 2 GA trial of Xelafaslatide
  • [H5] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H5] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H5] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H5] Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline
  • [H5] The Retina TL;DR with Dr. Weng: Targeting the Fas signaling pathway with David Zacks, MD, PhD
  • [H5] Evaluating Safety and Clinical Confidence between Aflibercept 8 mg and 2 mg in Retinal Vascular Diseases
  • [H5] Management Approaches for Suboptimal Responders in AMD, DME, and RVO
  • [H5] Comparing Aflibercept 8 mg and Faricimab in RVO
  • [H5] Insights from Privotal Trials for Aflibercept (8 mg) in RVO
  • [H5] Evaluating Retinal Drying, Durability and IOP Management with Second-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
  • [H5] Loading Dose Adjustments and Treatment Switching Strategies in Retinal Vascular Diseases
  • [H5] Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
  • [H5] Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal Vascular Diseases
  • [H5] Clinical Insights Shaping Real-World Decision-Making in Geographic Atrophy
  • [H5] Managing Geographic Atrophy in a 90-Year-Old Patient with Coexisting Neovascular AMD and Recurrent CNV Activation
  • [H5] Evaluating Progressive Multifocal Geographic Atrophy in an Asymptomatic 81-Year-Old Male

Bilder

Es konnten 135 Bilder auf dieser Webseite gefunden werden.

Bei 23 Bilder(n) fehlt ein ALT-Attribut. Fügen Sie ALT-Attribute zu Ihren Bildern, um die Bedeutung der Bilder für Suchmaschinen zugänglich zu machen.

Text/HTML Verhältnis

Anteil : 3%

Das Text zu HTML Code Verhältnis dieser Webseite ist niedriger als 15 Prozent, was bedeutet, dass Sie mehr Inhalte für Ihre Webseite schreiben sollten.

Flash

Perfekt, denn es wurde kein Flash auf Ihrer Webseite gefunden.

IFrame

Großartig, denn Sie verwenden keine IFrames auf Ihrer Webseite.

URL Rewrite

Gut. Ihre Links sind für Suchmaschinen gut lesbar (sprechende Links)!

Underscores in the URLs

Perfekt! Wir haben keine Unterstriche in Ihren Links entdeckt.

In-page links

We found a total of 89 links including 0 link(s) to files

Anker Typ Natürlich
All News intern natürliche Links
Blogs intern natürliche Links
All Videos intern natürliche Links
Case-Based Roundtable Series intern natürliche Links
Eichenbaum Acorns intern natürliche Links
Expert Interviews intern natürliche Links
Eyeviews intern natürliche Links
Insights intern natürliche Links
Medical World News extern natürliche Links
Podcasts intern natürliche Links
Rapid Readouts intern natürliche Links
The Retina TL;DR intern natürliche Links
Viewpoints intern natürliche Links
Conference Coverage intern natürliche Links
Conference Listing intern natürliche Links
Modern Retina Digital Edition intern natürliche Links
Supplements And Featured Publications intern natürliche Links
Between the Lines intern natürliche Links
CME/CE intern natürliche Links
EYLEA 8mg for nAMD and DME Treatment intern natürliche Links
Sponsored Resources intern natürliche Links
Partners intern natürliche Links
Subscribe intern natürliche Links
AMD intern natürliche Links
Wet AMD intern natürliche Links
Biosimilar intern natürliche Links
Diabetic Macular Edema intern natürliche Links
Diabetic Eye Awareness intern natürliche Links
Diabetic Retinopathy intern natürliche Links
Geographic Atrophy intern natürliche Links
Imaging intern natürliche Links
Inherited Retinal Diseases intern natürliche Links
Ophthalmology intern natürliche Links
RVO intern natürliche Links
Retina Technology intern natürliche Links
Retinal Surgery intern natürliche Links
Uveitis intern natürliche Links
Geographic Atrophy intern natürliche Links
ISS 2026 highlights advances in ophthalmic imaging for retinal practice intern natürliche Links
FLORetina: Inadvertent anti-VEGF interval increases during the COVID-19 pandemic intern natürliche Links
Treating MacTel: First identify patient candidates and appropriate eye selection intern natürliche Links
A medical fellow finds some magic at the AAO Annual Meeting intern natürliche Links
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight intern natürliche Links
FLORetina 2025: Updates on tinlarebant in adolescent Stargardt disease intern natürliche Links
FLORetina 2025: Long-term follow-up in pediatric gene therapy intern natürliche Links
FLORetina 2025: Mary Elizabeth Hartnett on ROP research and risk management intern natürliche Links
FLORetina 2025: Reframing retinal disease through the lens of choroidal health intern natürliche Links
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage intern natürliche Links
Martin David Harp intern natürliche Links
Christina Y. Weng, MD, MBA, FASRS intern natürliche Links
View All intern natürliche Links
Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO intern natürliche Links
Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast intern natürliche Links
Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS intern natürliche Links
The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD intern natürliche Links
Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME intern natürliche Links
The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD intern natürliche Links
PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice intern natürliche Links
PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice intern natürliche Links
Integrating AI to manage DR in a primary care setting intern natürliche Links
What to expect from virtual AAO 2020 intern natürliche Links
View More intern natürliche Links
Navigating geographic atrophy from biomarkers to bilateral therapy intern natürliche Links
8 things to know about aflibercept 8 mg for retinal vascular disease intern natürliche Links
Inside the mindset of an early adopter intern natürliche Links
Challenges for young physicians treating patients with GA intern natürliche Links
AAO highlight: Looking ahead to 2026 intern natürliche Links
How AI is reshaping ophthalmology in 2025 and beyond intern natürliche Links
Seeing the difference: Multimodal imaging for AMD and GA intern natürliche Links
Ryan Livingston intern natürliche Links
Lynda Charters intern natürliche Links
Kevin Kunzmann intern natürliche Links
Jeffry D. Gerson, OD, FAAO intern natürliche Links
Theodore Leng, MD, MS intern natürliche Links
Sheryl Stevenson intern natürliche Links
Joshua Mali, MD intern natürliche Links
Arshad M. Khanani, MD, MA, FASRS intern natürliche Links
Modern Retina Staff Reports intern natürliche Links
Jayanth Sridhar, MD intern natürliche Links
Matt Hoffman intern natürliche Links
Sheila Setork, OD intern natürliche Links
About intern natürliche Links
Advertise intern natürliche Links
Editorial intern natürliche Links
Contact Us intern natürliche Links
Terms and Conditions intern natürliche Links
Privacy intern natürliche Links
Do Not Sell My Personal Information extern natürliche Links
Home intern natürliche Links

SEO Suchbegriffe

Suchbegriffswolke

video cope cme faao view retinal fasrs track management more

Keywords Consistency

Suchbegriff Inhalt Seitentitel Suchbegriffe Seitenbeschreibung Überschriften
more 64
view 52
video 44
track 35
faao 24

Benutzerfreundlichkeit

URL

Domain : modernretina.com

Länge : 16

Favoriten Icon

Gut. Die Webseite hat ein Favicon.

Druckeigenschaften

Es konnten keine druckfreundlichen CSS-Angaben gefunden werden.

Sprache

Gut, denn Sie haben in den META-Elementen eine Sprache deklariert: en.

Dublin Core

Diese Webseite nutzt nicht die Vorteile der Dublin Core Elemente.

Dokument

Doctype

HTML 5

Verschlüsselung

Perfekt, denn Ihre Webseite deklariert einen Zeichensatz: UTF-8.

W3C Validität

Fehler : 0

Warnungen : 0

E-Mail Datenschutz

Achtung! Es wurde mindestens eine E-Mail Adresse im Klartext auf Ihrer Webseite gefunden. Benutzen Sie dieses kostenlose Werkzeug um E-Mail Adressen vor SPAM zu schützen.

Veraltetes HTML

Sehr gut! Sie verwenden aktuelle HTML Tags in Ihrem Webseitenquelltext.

Tipps zur Webseitengeschwindigkeit

Sehr gut, denn Ihre Webseite benutzt keine verschachtelten Tabellen.
Schlecht, denn es wurden CSS-Angaben in HTML-Elementen entdeckt. Diese Angaben sollten in ein entsprechendes CSS-Stylesheet verlagert werden.
Gut, denn Ihre Webseite enthält nur wenig CSS-Dateien.
Nicht so gut, denn Ihre Webseite enthält viele Javascript-Dateien (mehr als 6).
Gut! Sie nutzen die Vorteile von gzip.

Mobile

Mobile Optimierung

Apple Icon
META Viewport Tag
Flash Inhalt

Optimierung

XML-Sitemap

Perfekt! Ihre Seite hat eine XML-Sitemap.

https://www.modernretina.com/sitemap.xml
https://www.modernretina.com/sitemap-news.xml

Robots.txt

https://modernretina.com/robots.txt

Sehr gut! Ihre Webseite enthält eine robots.txt-Datei.

Analytics

Sehr gut, Ihre Website hat ein Analyse-Tool.

   Google Analytics

PageSpeed Insights

Gerät
Kategorien

Free SEO Testing Tool

Free SEO Testing Tool ist ein kostenloses SEO Werkzeug zur Analyse Ihrer Webseite